News & Views
News,
Telix today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous…
Read more
Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:…
Read more
Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be…
Read more
Telix today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University…
Read more
Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 24 May…
Read more
Telix is pleased to provide a video recording of the joint webcast with Telix’s exclusive partner for the Greater China market, Grand Pharma held on 20 April 2023. …
Read more
Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise…
Read more
Telix today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both…
Read more
Telix today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in…
Read more
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023 on Monday 17 April 2023 at market…
Read more